 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | KQ-2002 / Novatim Immune Therap
Trial completion date, Trial primary completion date, CAR T-Cell Therapy: Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory B Cell Lymphoma (clinicaltrials.gov) - Dec 28, 2023
P1/2, N=24, Recruiting, Sponsor: Shanxi Province Cancer Hospital
Trial completion date: Dec 2023 --> Oct 2025 | Trial primary completion date: Dec 2021 --> Oct 2024
- | KQ-2003 / Shanghai Keqi Pharma
Trial completion date, Trial primary completion date, CAR T-Cell Therapy: Targeting CD19 and BCMA CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Dec 28, 2023
P1/2, N=24, Recruiting, Sponsor: Shanxi Province Cancer Hospital
Trial completion date: Dec 2023 --> Oct 2025 | Trial primary completion date: Dec 2021 --> Oct 2024 Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Jan 2022 --> Sep 2024
- | KQ-2002 / Novatim Immune Therap
New P1/2 trial, CAR T-Cell Therapy: Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory B Cell Lymphoma (clinicaltrials.gov) - Jan 19, 2021
P1/2, N=24, Recruiting, Sponsor: Shanxi Province Cancer Hospital
- | New P1/2 trial, CAR T-Cell Therapy: Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Acute B Lymphocytic Leukemia (clinicaltrials.gov) - Jan 18, 2021
P1/2, N=24, Recruiting, Sponsor: Shanxi Province Cancer Hospital
- | KQ-2003 / Shanghai Keqi Pharma
New P1/2 trial, CAR T-Cell Therapy: Targeting CD19 and BCMA CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Jan 18, 2021
P1/2, N=24, Recruiting, Sponsor: Shanxi Province Cancer Hospital